Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology

Clinics in Dermatology

Volumn 21, Issue 1, 2003, Pages 64-70

  Wesson, Karen M ^a   Lerner, Daniel S ^a   Silverberg, Nanette B ^a   Weinberg, Jeffrey M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; LINEZOLID; OXACILLIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ATROPHY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BINDING AFFINITY; BIOAVAILABILITY; BIOTRANSFORMATION; BLEEDING; BURNING SENSATION; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; EDEMA; FATTY ACID SYNTHESIS; FIRST PASS EFFECT; HEADACHE; HUMAN; HYPERSENSITIVITY; MEMBRANE POTENTIAL; MEMBRANE RUPTURE; MUSCLE WEAKNESS; NAUSEA; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; PSEUDOMEMBRANOUS COLITIS; QT INTERVAL; RASH; RNA TRANSLATION; SIDE EFFECT; SKIN ABSCESS; SKIN INFECTION; SOFT TISSUE INFECTION; TARGET ORGAN; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT FAILURE;

EID: 0037214897     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00321-8     Document Type: Article

References (40)

1. Reduced susceptibility of Staphylococcus aureus to Vancomycin-Japan 1996. MMWR. 46:1997;624-626.
2. Zyvox [package insert]. Kalamazoo, MI; Pharmacia & Upjohn Company, 2000.
3. Slee A.M., Wuonola M.A., McRipley R.J., et al. Oxazolidinones, a new class of synthetic antibacterial agents in vitro and in vivo activities of DuP 105 and DuP 721 . Antimicrob Agents Chemother. 31:1987;1791-1797.
4. Swaney S.M., Aoki H., Ganoza M.C., et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 42:1998;3251-3255.
5. Eliopoulos G.M., Wennersten C.B., Gold H.S., et al. In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother. 40:1996;1745-1747.
6. Ford C.W., Hamel J.C., Wilson D.M., et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother. 40:1996;1508-1513.
7. Jorgensen J.H., McElmeel M.L., Trippy C.W. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother. 41:1997;465-467.
8. Mercier R.C., Penzak S.R., Rybak S.R. In vitro activities of investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 41:1997;2573-2575.
9. Noskin G.A., Siddiqui F., Stosor V., et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother. 43:1999;2059-2062.
10. Clemett D., Markham A. Linezolid. Drugs. 59:2000;815-827.
11. th International Congress on Infectious Diseases (Buenos Aires). Boston: International Society of Infectious Diseases, 2000.
12. th International Congress on Infectious Diseases (Buenos Aires). Boston: International Society of Infectious Diseases, 2000.
13. Batts D.H. Linezolid - a new option for treating gram-positive infections. Oncology. (Suppl 6):2000;23-29.
14. Zurenko GE, Todd WM, Hafkin B, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract]. Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy: 1999 Sept 26-29; San Francisco, p. 118.
15. Barrett J.F. Linezolid Pharmacia Corp. Curr Opin Invest Drugs. 1:2000;181-187.
16. Bryson H.M., Spencer C.M. Quinupristin-dalfopristin antibacterial activity, pharmokinetic profile, therapeutic trials, tolerability and current status . Drugs. 52:1996;406-415.
17. Cocito C., Di Giambattista M., Nyssen E., et al. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother. 39:(Suppl A):1997;7-13.
18. Lamb H.M., Figgitt D.P., Faulds D. Quinupristin/dalfopristin. A review of its use in the management of serious gram-positive infections. Drugs. 58:1999;1061-1097.
19. Landman D., Quale J.M. Management of infections due to resistant enterococci a review of therapeutic options . J Antimicrob Chemother. 40:1997;161-170.
20. Linden P.K., Pasculle A.W., McDevitt D. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia comparison with a control cohort . J Antimircob Chemother. 39:(Suppl A):1997;145-151.
21. Nichols R.L., Graham D.R., Barriere S.L., et al. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin . J Antimicrob Chemother. 44:1999;263-273.
22. Fagon J.-Y., Patrick H., Haas D.W., et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med. 161:2000;753-762.
23. Moellering R.C., Linden P.K., Reinhardt, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococci faecium. J Antimicrob Chemother. 44:1999;251-261.
24. Talbot G.H., Zhu G.R. Characterization of arthralgias/myalgias associated with quinupristin/dalfopristin (Synercid) [abstract]. Clin Infect Dis. 27:1998;965.
25. Bompart F, Dorr M, Bekele T, et al. Overview of the safety and tolerability of quinupristin/dalfopristin (Synercid, RP 59500) in the global development program [abstract no. 2318]. Twentieth International Congress of Chemotherapy; 1997 Jun 29: Sydney:44-5.
26. Rhone-Poulenc Rorer. Synercid (quinupristin/dalfopristin): expert report on clinical documentation. 15 Sep 1997.
27. Rhone-Poulenc Rorer. Synercid (quinupristin/dalfopristin): integrated summary of safety. 14 Jul 1997.
28. Rhone-Poulenc Rorer Pharmaceutical Inc. Prescribing information. Synercid IV (quinupristin and dalfopristin for injection). Collegeville, PA: 1999.
29. Canepari P., Boaretti M., Del Mar Lleo M., et al. Lipoteichoic acid as a new target for activity of antibiotics mode of action of daptomycin . Antimicrob Agents Chemother. 34:1990;1220-1226.
30. Boaretti M., Canepari P., Del Mar Lleo M., et al. The activity of daptomycin on Enterococcus faecium protoplasts indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis . J Antimicrob Chemother. 31:1993;227-235.
31. Alborn W.E. Jr, Allen N.E., Preston D.A. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother. 35:1991;2282-2287.
32. Allen N.E., Alborn W.E. Jr, Hobbs J.N. Jr. Identification of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother. 35:1991;2639-2642.
33. Woodworth J.R., Nyhart E.H., Brier G.L., et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic in health volunteers. Antimicrob. Agents Chemother. 36:1992;318-325.
34. Garrison M.W., Vance-Bryan K., Larson T.A., et al. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 34:1990;1925-1931.
35. Ryback M.J., Bailey E.M., Lamp K.C., et al. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. 36:1992;1109-1114.
36. Tally F.P., Zeckel M., Wasilewski M.M., et al. Daptomycin a novel agent for gram-positive infections . Exp Opin Invest Drugs. 8:1999;1223-1228.
37. Ryback M.J., Hershberger E., Moldovan T., et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and resistant strains. Antimicrob Agents Chemother. 44:2000;1062-1066.
38. Stephenson J. Researchers describe latest strategies to combat antibiotic-resistant microbes. JAMA. 285:2001;2317-2318.
39. Oleson F.B. Jr, Berman C.L., Kirkpatrick J.B., et al. One daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 44:2000;2948-2953.
40. Hanberger H., Nilsson L.E., Maller R., et al. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of calcium and albumin on these drugs. Antimicrob Agents Chemother. 35:1991;1710-1716.